FDA Recalls Generic ADHD Medication Due to Dissolution Test Failures

The U.S. Food and Drug Administration (FDA) has announced a nationwide recall of lisdexamfetamine dimesylate capsules, a generic alternative to the brand-name ADHD medication Vyvanse. Sun Pharmaceutical Industries Inc. initiated the voluntary recall on October 28, 2025, after the medication failed to meet dissolution standards during laboratory testing. The FDA classified this as a Class II recall on October 30, indicating the potential for temporary or medically reversible health consequences.